These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Narrow-band ultraviolet B phototherapy for the treatment of vitiligo: evidence against an autoimmune pathogenesis. Engin B; Baysal I; Reisli I; Ozdemir M; Toy H J Eur Acad Dermatol Venereol; 2008 Dec; 22(12):1520-1. PubMed ID: 18355207 [No Abstract] [Full Text] [Related]
23. Broadband targeted UVB phototherapy for localized vitiligo: a retrospective study. Akar A; Tunca M; Koc E; Kurumlu Z Photodermatol Photoimmunol Photomed; 2009 Jun; 25(3):161-3. PubMed ID: 19438998 [TBL] [Abstract][Full Text] [Related]
24. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. Scherschun L; Kim JJ; Lim HW J Am Acad Dermatol; 2001 Jun; 44(6):999-1003. PubMed ID: 11369913 [TBL] [Abstract][Full Text] [Related]
25. An innoxious combination for depigmentation. Hongal AA; Revathi TN; Sijimol MV; Ramamurthy R Indian J Dermatol Venereol Leprol; 2021; 87(6):865-866. PubMed ID: 34623038 [No Abstract] [Full Text] [Related]
26. [Vitiligo--loss of cutaneous pigmentation]. Sitek JC Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2370-2. PubMed ID: 16998548 [TBL] [Abstract][Full Text] [Related]
27. Dermatoscopy of blue vitiligo. Chandrashekar L Clin Exp Dermatol; 2009 Jul; 34(5):e125-6. PubMed ID: 19438538 [TBL] [Abstract][Full Text] [Related]
28. Halo congenital naevus in a middle-aged patient with vitiligo. Leow LJ; Goh BK Australas J Dermatol; 2008 Nov; 49(4):229-32. PubMed ID: 18855788 [TBL] [Abstract][Full Text] [Related]
29. Psoralen plus ultraviolet A irradiation-induced lentigines arising in vitiligo: involvement of vitiliginous and normal appearing skin. Abdel Naser MB; Wollina U; El Okby M; El Shiemy S Clin Exp Dermatol; 2004 Jul; 29(4):380-2. PubMed ID: 15245535 [TBL] [Abstract][Full Text] [Related]
35. Treatment of vitiligo with broadband ultraviolet B and vitamins. Don P; Iuga A; Dacko A; Hardick K Int J Dermatol; 2006 Jan; 45(1):63-5. PubMed ID: 16426381 [TBL] [Abstract][Full Text] [Related]
36. The hair follicle melanocytes in vitiligo in relation to disease duration. Anbar TS; Abdel-Raouf H; Awad SS; Ragaie MH; Abdel-Rahman AT J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):934-9. PubMed ID: 19453793 [TBL] [Abstract][Full Text] [Related]
37. A rational approach to the treatment of vitiligo and other hypomelanoses. Hercogová J; Buggiani G; Prignano F; Lotti T Dermatol Clin; 2007 Jul; 25(3):383-92, ix. PubMed ID: 17662904 [TBL] [Abstract][Full Text] [Related]
38. Vitiligo: new and emerging treatments. Lotti T; Gori A; Zanieri F; Colucci R; Moretti S Dermatol Ther; 2008; 21(2):110-7. PubMed ID: 18394085 [TBL] [Abstract][Full Text] [Related]
39. Stable vitiligo treated by a combination of low-dose oral pulse betamethasone and autologous, noncultured melanocyte-keratinocyte cell transplantation. Mulekar SV Dermatol Surg; 2006 Apr; 32(4):536-41. PubMed ID: 16681662 [TBL] [Abstract][Full Text] [Related]
40. Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. Parsad D; Kanwar AJ; Kumar B J Eur Acad Dermatol Venereol; 2006 Feb; 20(2):175-7. PubMed ID: 16441626 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]